Cancer drugmaker Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen Inc as too low but still is considering selling itself.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment